When a heart attack blocks blood flow, heart muscle cells in the affected area can die within hours. Unlike tissues such as the skin or liver, the heart has very little ability to regenerate. Instead, the damaged area is replaced with scar tissue, which can't contract like healthy muscle. Over time, this loss of function can weaken the heart and increase the risk of chronic heart failure.
Pilar Ferrer, a biologist and graduate of Favaloro University in Argentina, is developing an experimental hydrogel through her startup, Amnova Biotech. Inspired by the amniotic membrane—a placental tissue already used in regenerative medicine—the gel is designed to be injected into damaged heart tissue, where it serves as a supportive scaffold that may encourage the body's own repair processes rather than leaving behind only scar tissue.
So far, studies in sheep have shown encouraging results, including smaller areas of damage and improved heart function after treatment. While these findings are exciting, they're still in the early stages. Human clinical trials are not expected to begin until around 2028, and many therapies that succeed in animals ultimately fail to produce the same results in people.
If future research confirms its effectiveness, this regenerative strategy could represent a major shift in how heart attack damage is treated. Would you be interested in seeing treatments that focus on rebuilding heart tissue instead of simply managing permanent scarring?
0 commentaires:
Enregistrer un commentaire